All In Biotech

Drug Trial Radar · NCT05599984

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

288

Actual

Start

Dec 5, 2022

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Oct 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy and in combination with budigalimab, carboplatin, or cisplatin. ABBV-706 is an investigational drug being developed for the treatment of small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine carcinomas (NECs). There are multiple treatment arms in this study. Participants will either receive ABBV-706 as a single agent or in combination with budigalimab (another investigational drug), carboplatin or cisplatin at different doses. Approximately 319 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), ABBV-706 will be intravenously infused in escalating doses as a monotherapy until the maximum tolerated dose (MTD) is determined in participants with SCLC, high-grade CNS tumors, and high-grade NECs. In part 2, multiple doses will be selected from Part 1 and SCLC participants will be assigned to one of these doses in a randomized fashion to determine the recommended Phase 2 dose. In Part 3a, participants with SCLC or NECs will receive ABBV-706 in combination with budigalimab intravenously every 3 weeks. In Part 3b participants with SCLC or NECs will receive ABBV-706 in combination with either carboplatin or cisplatin intravenously. In Part 4a, participants with CNS tumors will receive ABBV-706 intravenously at a dose determined from Part 1. In Part 4b, participants with NECs will receive ABBV-706 intravenously at a dose selected from Part 1. The estimated duration of the study is up to 4 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Conditions

  • Advanced Solid Tumors

Interventions

  • ABBV-706Drug

    Intravenous (IV) Infusion

  • CisplatinDrug

    Intravenous infusion

  • BudigalimabDrug

    IV Infusion

  • CarboplatinDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse Events (AE)Time frame: Up to Approximately 2 Years
  2. Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706Time frame: Up to Approximately 2 Years
  3. Time to Cmax (Tmax) of ABBV-706Time frame: Up to Approximately 2 Years
  4. Terminal Phase Elimination Half-Life (t1/2) of ABBV-706Time frame: Up to Approximately 2 Years
  5. Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706Time frame: Up to Approximately 2 Years
  6. Antidrug Antibodies (ADAs)Time frame: Up to Approximately 2 Years
  7. Neutralizing Antibodies (nAbs)Time frame: Up to Approximately 2 Years
  8. Percentage of Participants with Objective Response, for Participants with Extracranial Solid TumorsTime frame: Up to Approximately 2 Years
  9. Recommended Phase 2 Dose (RP2D) of ABBV-706Time frame: Up to Approximately 2 Years
  10. Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) TumorsTime frame: Up to Approximately 2 Years
  11. Duration of response (DOR) for Participants with Confirmed CR/PRTime frame: Up to Approximately 2 Years
  12. Percentage of Participants with Clinical BenefitTime frame: Up to Approximately 2 Years
  13. Progression-Free Survival (PFS)Time frame: Up to Approximately 2 Years
  14. Overall survival (OS)Time frame: Up to Approximately 2 Years

Locations

66 sites in 10 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Ctr /ID# 260129

    Gilbert, Arizona

  • City Of Hope Comprehensive Cancer Center /ID# 271295

    Duarte, California

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 259884

    Irvine, California

  • Yale New Haven Hospital /ID# 246647

    New Haven, Connecticut

  • Georgetown University Hospital /ID# 255352

    Washington D.C., District of Columbia

  • University of Chicago Medical Center /ID# 256334

    Chicago, Illinois

  • Fort Wayne Medical Oncology and Hematology, Inc /ID# 260130

    Fort Wayne, Indiana

  • University of Iowa Hospitals and Clinics /ID# 246638

    Iowa City, Iowa

  • Barbara Ann Karmanos Cancer In /ID# 261799

    Detroit, Michigan

  • Henry Ford Hospital /ID# 246648

    Detroit, Michigan

  • START Midwest /ID# 251257

    Grand Rapids, Michigan

  • St. Lukes Hosp. of Kansas City /ID# 259958

    Kansas City, Missouri

  • Washington University-School of Medicine /ID# 246286

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center-Koch Center /ID# 246303

    New York, New York

  • Duke Cancer Center /ID# 246285

    Durham, North Carolina

  • UH Cleveland Medical Center /ID# 246641

    Cleveland, Ohio

  • Univ Oklahoma HSC /ID# 250884

    Oklahoma City, Oklahoma

  • Tennessee Oncology, PLLC /ID# 246283

    Nashville, Tennessee

  • University of Texas MD Anderson Cancer Center /ID# 246287

    Houston, Texas

  • South Texas Accelerated Research Therapeutics /ID# 248946

    San Antonio, Texas

  • University of Utah /ID# 246640

    Salt Lake City, Utah

  • Northwest Medical Specialties - Tacoma /ID# 262801

    Tacoma, Washington

  • Chris O'Brien Lifehouse /ID# 259087

    Camperdown, New South Wales, Australia

  • The Kinghorn Cancer Centre /ID# 260874

    Darlinghurst, New South Wales, Australia

  • Austin Health and Ludwig Institute for Cancer Research /ID# 255174

    Heidelberg, Victoria, Australia

  • Peter MacCallum Cancer Ctr /ID# 259197

    Melbourne, Victoria, Australia

  • Cancer Hospital - Chinese Academy Of Medical Sciences /ID# 270044

    Beijing, Beijing Municipality, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 270038

    Wuhan, Hubei, China

  • First Affiliated Hospital of China Medical University /ID# 270041

    Shenyang, Liaoning, China

  • Shanghai Chest Hospital /ID# 270036

    Shanghai, Shanghai Municipality, China

  • Shanghai East Hospital /ID# 268615

    Shanghai, Shanghai Municipality, China

  • Shanghai Pulmonary Hospital /Id# 270039

    Shanghai, Shanghai Municipality, China

  • Institut Régional du Cancer Montpellier /ID# 265086

    Montpellier, France

  • Institut Bergonie /ID# 258655

    Bordeaux, Gironde, France

  • Institut Gustave Roussy /ID# 260334

    Villejuif, Val-de-Marne, France

  • Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin /ID# 259413

    Berlin, Germany

  • Klinikum der Universitaet Muenchen - Campus Innenstadt /ID# 259412

    Munich, Bavaria, Germany

  • Universitaetsklinikum Carl Gustav Carus Dresden /ID# 259414

    Dresden, Saxony, Germany

  • Rambam Health Care Campus /ID# 255059

    Haifa, Israel

  • Hadassah Medical Center-Hebrew University /ID# 255147

    Jerusalem, Israel

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.